Regorafenib Phase I Study in Mainland Chinese Patients
The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors.

The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib
Oncology
DRUG: Regorafenib (Stivarga, BAY73-4506)
Cmax (maximum drug concentration in plasma), Cycle 0 day 1, 0、0.5、1、2、3、4、6、8、12、24、36、48、72、96 hours|AUC(0-24) (AUC from time 0 h to time 24 h post-administration), Cycle 0 day1, 0、0.5、1、2、3、4、6、8、12、24 hours|AUC(0-tlast) (AUC from time zero to the last data point>LLOQ), Cycle0 day 1, 0、0.5、1、2、3、4、6、8、12、24、36、48、72、96 hours|Cmax.ss (Cmax at steady-state during a dosage interval), Cycle 1 day 21, 0,0.5,1,2,3,4,6,8,12,24,36,48,72,96 hours|AUCt.ss (AUC for the dosing interval at steady-state), cycle 1 day 21 0,0.5,1,2,3,4,6,8,12,24 hours
Number of participants with adverse events as a measure of safety and tolerability, Up to 30 days|Tumor Response base don RECIST 1.1 criteria, Up to 30 days
The primary objective of this study is to define the pharmacokinetic of Regorafenib administered orally as a single agent in Chinese patients with advance solid tumors.

The second objective include the evaluation of safety, tolerability, and efficacy of Chinese patents treated with Regorafenib